Table 1.

Main effect and other variables included in analyses

Groups and variables
Analysis: CMV serostatus
Composite: main effect variable (groups by serostatus/donor/PTCy)
R+ HaploCy D+/R– HaploCy D–/R– HaploCy R+ SibCy D+/R– SibCy D– /R– SibCy R+ SibCNI D+/R– SibCNI D–/R– Sib CNI (ref)
Analysis: CMV DNAemia by day 180
Composite: main effect variable (groups by donor/PTCy/CMV infection)
HaploCy with CMV DNAemia HaploCy with no CMV DNAemia SibCy with CMV DNAemia SibCy with no CMV DNAemia SibCNI with CMV DNAemia SibCNI with no CMV DNAemia (reference)
Other variables examined in multivariate analyses
Graft type: marrow (reference) vs PB D/R gender: M-M (reference) vs M-F vs F-F vs F-M HCT-CI: 0 (reference) vs 1-2 vs 3-4 vs 5+ Disease risk: AL favorable cyto, early/intermediate stage (reference) vs AL intermediate/nl cyto, early stage, vs AL poor cyto, early stage; vs AL intermediate/nl cyto, intermediate stage vs AL poor cyto, intermediate stage vs AL advanced (all cyto categories) vs MDS very low/low vs MDS intermediate vs MDS high/very high Recipient age (y): ≤20 (reference) vs 21-40 vs 41-60 vs >60 KPS: ≥90 (reference) vs 80-89 vs <80 Conditioning intensity: myeloablative (reference) vs RIC TBI: no (reference) vs yes Time from diagnosis to HCT (mo): <6 (reference) vs 6-12 vs >12 Year of HCT: 2012-2014 (reference) vs 2015-2017 No. of viral infections: 0 vs 1 vs 2 vs 3+ Neutrophil engraftment prior to infection (time dependent) Coinfection: no infection (reference) vs viral + coinfection vs viral + coinfection vs other infection by day 180 Acute GVHD grade 2-4 prior to CMV infection (time dependent)

Because of the interactions between donor type, use of PTCy, and other variables of interest in each analysis, composite variables were for the CMV serostatus analysis and CMV DNAemia analysis. These composite variables also served as the main effect variables analyzed in their respective multivariate analyses that examined them with respect to the other variables of interest. AL, acute leukemia; BM, bone marrow; cyto, cytogenetics; F, female; KPS, Karnosfky performance status; M, male; nl, normal; PB, peripheral blood; Sib, sibling; TBI, total body irradiation.